ALLOX

Name

ALLOX

Legal name

Allostery Exploration Technologies S.L.

Website

https://allox.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro industry

PRIMARYHLAAAIAE

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAL

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAC

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Allosteric drug discovery
• Deep mutagenesis platform
• AI drug discovery
• Protein function analysis
• Computational biology platform

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Discovery Partnerships: ALLOX partners with pharmaceutical and biotech companies to apply their proprietary allosteric drug discovery platform for identifying and validating drug targets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

ALLOX develops a genetics- and AI-driven drug discovery platform combining high-throughput deep mutagenesis with computational biology to identify and validate allosteric sites on proteins. The platform consists of two integrated components: the ALLOX Experimental Platform (high-throughput protein variant generation) and the ALLOX Computational Platform (AI/ML analysis of biophysical parameters). ALLOX partners with pharmaceutical and biotechnology companies to apply this technology for novel drug target discovery in oncology and other therapeutic areas.

Product overview

ALLOX is a biotech company spun off from the Wellcome Sanger Institute and CRG (Centre for Genomic Regulation) that offers an integrated platform combining genetics and AI to learn biophysical parameters governing protein function. The company consists of two core offerings: the ALLOX Experimental Platform (a high-throughput system using deep mutagenesis for protein analysis and allosteric drug discovery) and the ALLOX Computational Platform (an AI-powered computational system for data analysis and structural biology). Together, these platforms enable the discovery and scaling of allosteric sites for therapeutic applications.

Differentiator

Problem solved

Functional benefit

Products and services

• ALLOX Experimental Platform A proprietary high-throughput experimental platform that uses deep mutagenesis to systematically explore protein variants, scaling discovery of allosteric sites from tens to hundreds to thousands of variants. Designed for pharmaceutical and biotech partners engaged in target identification and validation. Co-invented by ALLOX's CEO Júlia Domingo.
• ALLOX Computational Platform An AI-powered computational platform that analyzes biophysical parameters governing protein function, develops tools for structural biology, and ensures alignment between computational and lab operations. Uses machine learning trained on large-scale mutagenesis data to predict allosteric sites. Co-invented by ALLOX's CTO André Faure. Runs on Seqera Platform (Nextflow) pipelines deployed on Google Cloud.

Quantifiable outcome

• ALLOX scientists used large-scale genomics and machine learning to study over 140,000 versions of Aβ42 peptide to map the first step in Alzheimer's protein aggregation

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Centre for Genomic Regulation (CRG)coreStrategic or Co-development PartnerALLOX is a spin-off of CRG (Centre for Genomic Regulation). Ben Lehner serves as ICREA Professor at CRG. The company originated from research conducted at CRG.
• Wellcome Sanger InstitutecoreStrategic or Co-development PartnerBen Lehner, Chief Scientific Advisor and co-founder of ALLOX, serves as Head of Generative and Synthetic Genomics at the Wellcome Sanger Institute. The institute represents a key academic collaboration.
• Green Lab CertifiedminorOthersALLOX has achieved Green Lab Certification, demonstrating commitment to sustainable laboratory practices.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Schrödinger: Schrödinger is an established computational chemistry and molecular simulation platform serving pharma R&D globally. Broader in scope than ALLOX (small molecule plus biologics, broader software suite), but overlaps in AI-driven physics-based prediction for protein function and drug discovery.
• Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML to discover therapeutics at scale across many targets. Comparable to ALLOX in combining experimental high-throughput data with ML, but operates a much broader platform with internal pipeline and significant capital base.
• Isomorphic Labs: Isomorphic Labs (DeepMind spin-off) applies AlphaFold-derived AI to drug discovery and operates a deep pharma partnership model. Comparable to ALLOX in AI-first protein structure/function prediction and partnership-led commercialization, though with vastly greater resources.

Direct peers

• Generate Biomedicines: Generate Biomedicines combines generative AI with high-throughput experimental biology to design novel protein therapeutics. Comparable to ALLOX through its wet-lab-plus-AI integration and its platform-style discovery approach across diverse protein targets.
• Frontier Medicines: Frontier Medicines uses chemoproteomics and AI to drug allosteric and cryptic pockets on proteins. Directly comparable to ALLOX in target class (allosteric sites), modality (AI + experimental biology), and customer model (pharma partnerships).
• Nabla Bio: Nabla Bio designs novel proteins using AI combined with high-throughput wet-lab validation, partnering with pharma to expand the druggable surface. Comparable to ALLOX through deep mutagenesis, AI-guided protein function prediction, and a pharma partnership go-to-market model.
• Relay Therapeutics: Relay Therapeutics uses protein motion and computational chemistry to discover allosteric and conformationally-selective small molecules. Directly comparable to ALLOX in the focus on allosteric mechanisms and the combination of computation with experimental validation.
• Cradle Bio: Cradle applies machine learning to protein engineering and design, working with pharma and biotech customers to accelerate biologics discovery. Closely comparable to ALLOX in combining ML with experimental protein science to enable partner-driven discovery workflows.

Emerging players

• Profluent Bio: Profluent Bio uses large language models trained on biological sequence data to design novel proteins. Comparable to ALLOX in AI-driven protein engineering and partnership opportunities, though Profluent focuses on generative design rather than systematic mutagenesis-based function mapping.
• Insitro: Insitro applies machine learning to high-throughput biology for target discovery and therapeutic development. Comparable to ALLOX in combining ML with experimental data generation, though Insitro focuses more on cellular phenotypic data and internal pipeline development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ALLOXbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALLOX